What is Alopecia Areata?
Alopecia areata is an autoimmune condition in which the immune system mistakenly targets and attacks its own hair follicles, causing hair loss. The follicles are not destroyed — they remain alive — but are prevented from producing hair by the abnormal immune response. This is why, in many cases, hair can and does regrow.
Alopecia areata affects approximately 2% of the global population at some point in their lifetime — an estimated 6.8 million people in India alone. It can occur at any age, in both sexes, and across all ethnicities, though it most commonly presents before the age of 30.
The condition is not contagious. It is not caused by poor hygiene, stress alone, or any personal failing. It is a medical condition — as much as diabetes or rheumatoid arthritis — and deserves to be treated as such.
Types of Alopecia Areata
Patchy hair loss on the scalp (and sometimes beard in men) in distinct, usually coin-shaped areas. The patches may be single or multiple. Hair at edges may show "exclamation mark" pattern — characteristic of active disease.
Complete or near-complete loss of all scalp hair. All follicles on the scalp are affected by the autoimmune attack. More difficult to treat than standard alopecia areata, but remission and regrowth are possible.
Complete loss of all body hair — scalp, eyebrows, eyelashes, beard, and body hair. The most extensive form. Requires specialist systemic treatment including JAK inhibitors.
Hair loss following the periphery of the scalp — temples, hairline, and nape — in a snake-like band. Tends to be more persistent than patchy AA and more resistant to treatment.
Symptoms and Signs
- Patchy, smooth bald spots: Typically round or oval, on the scalp. The skin within patches is usually smooth, without scaling or scarring — distinguishing it from ringworm and scarring alopecia.
- Exclamation mark hairs: At edges of active patches, hairs are short and narrow at the base — characteristic of active, progressing alopecia areata.
- Nail changes: In 10–15% of patients, nails show pitting, ridging, or a sandpaper-like texture. Can precede, accompany, or follow hair loss.
- Sudden onset: Hair loss can appear very rapidly — sometimes overnight. Often discovered as a round bald patch by a hairdresser or family member.
- White regrowth: When hair begins to regrow, it may initially come in as fine white or grey hairs before regaining pigmentation — a very positive sign of recovery.
What Causes Alopecia Areata?
The Autoimmune Mechanism
Normally, hair follicles exist in a state of "immune privilege" — protected from immune attack. In alopecia areata, this protection breaks down. T-lymphocytes infiltrate the follicle bulb, releasing inflammatory cytokines (particularly interferon-gamma, IL-2, IL-15) that disrupt the hair growth cycle and suppress hair production.
These cytokines are the molecular targets of JAK inhibitors — targeted medications that block these pathways with remarkable efficacy in many patients.
Genetic & Environmental Factors
A family history of alopecia areata increases risk approximately 10-fold. The condition is strongly associated with other autoimmune conditions: thyroid disease, type 1 diabetes, vitiligo, psoriasis, and inflammatory bowel disease. Common triggers include significant physical illness (including COVID-19), severe emotional stress or trauma, and hormonal changes.
Treatment Options
First-Line Treatments
- Intralesional corticosteroids: Triamcinolone acetonide injections directly into bald patches — the most effective first-line treatment for limited alopecia areata. Multiple sessions every 4–6 weeks typically needed.
- Topical corticosteroids: High-potency topical steroids — less effective than intralesional injections but useful in children and for widespread disease.
- Minoxidil: Used adjunctively to stimulate regrowth once immune attack is suppressed by corticosteroid treatment.
Systemic Treatments — JAK Inhibitors (Major Breakthrough)
JAK inhibitors represent the most significant advance in alopecia areata treatment in decades. These oral medications block the JAK-STAT signalling pathway that drives the autoimmune attack on follicles. Baricitinib received FDA approval specifically for severe alopecia areata in 2022 — the first systemic drug approved for the condition. Clinical trials show substantial scalp hair regrowth in 30–40% of patients with at least 80% coverage recovery.
- Baricitinib (Olumiant): FDA-approved for severe alopecia areata (2022). Oral once daily.
- Ritlecitinib (Litfulo): FDA-approved for alopecia areata in adults and adolescents (2023).
- Tofacitinib: Used off-label with significant supporting evidence.
PRP & Other Adjuncts
- PRP Therapy: Emerging evidence supports PRP for alopecia areata — growth factors may suppress local inflammation and stimulate follicle recovery. Often used adjunctively with other treatments at Sapphire Roots.
- Immunotherapy (DPCP): Topical sensitising agents that create a controlled allergic reaction to redirect the immune response. Effective in some patients with extensive disease.
Hair transplant is generally not recommended for active alopecia areata because the immune attack can recur in transplanted follicles. For patients whose disease has been in stable remission for 2+ years, carefully planned transplant may be considered — with realistic understanding of recurrence risk.